放射性支架治疗胰腺胆道恶性肿瘤的实验研究
|
摘要
目的:验证放射性胰胆管塑料支架设计是否可行;评价放射性支架的可行性及安全性。方法:设计出放射性胰胆管塑料支架,动物实验进行可行性观察;以猪为研究对象胰胆管植入放射性支架,根据TPS计算的参考点照射剂量分为3组,A组50 Gy,B组100 Gy,C组150 Gy,术后随访观察。结果:支架通畅,支架上粒子没有发生脱落;部分支架移位,周围相邻脏器未发现明显异常。血液检查未发现明显严重异常。放射性胰管支架组,胰管壁正常形态结构消失;放射性胆管支架组未出现胆管穿孔,黏膜层上皮坏死,50Gy组黏膜腺体轻度增生,100 Gy组黏膜腺体无明显增生,150 Gy组黏膜腺体明显减少。结论:放射性胰胆管支架设计是可行的;支架是安全可行的;可以通过TPS设计出个体化的放射支架。
Objective : To test the feasibility of the radioactive plastic stents;To evaluate the feasibility and safety of the radioactive stents. Methods:Radioactive plastic stents were designed and its feasibility was tested in animal;Healthy pigs were used in this study ,they were were divided into three groups on the basis of radiation dose and implanted radioactive stents in the pancreatic or bile duct. The radiation dose of the reference point calculated by TPS was 50 Gy in Group A, 100 Gy in Group B,and 150 Gy in Group C. The pigs were followed up after implantation.Results: None of the stents were obstructed and all the seeds remained in the original position of the stents.The migration of some stents was found .There were no obvious dysfunction in the adjacent organs.There were no serious abnormalities noted on blood tests.In the groups of radioactive pancreatic duct stents, the normal morphological structure of the pancreatic duct wall disappeared;In the groups of radioactive bile duct stents,perforation of the common bile duct was not observed and necrosis of mucosal layer existed.In 50Gy Group mild hyperplasia of mucosal glands was seen. In 100Gy Group almost no hyperplasia of the mucosal glands could be found. In 150Gy Group mucosal glands obviously decreased .Conclusions:The design of radioactive plastic stents is feasible;The radioactive stents are safe and feasible;It is feasible to design a special radioactive stent through TPS.
Objective : To test the feasibility of the radioactive plastic stents;To evaluate the feasibility and safety of the radioactive stents. Methods:Radioactive plastic stents were designed and its feasibility was tested in animal;Healthy pigs were used in this study ,they were were divided into three groups on the basis of radiation dose and implanted radioactive stents in the pancreatic or bile duct. The radiation dose of the reference point calculated by TPS was 50 Gy in Group A, 100 Gy in Group B,and 150 Gy in Group C. The pigs were followed up after implantation.Results: None of the stents were obstructed and all the seeds remained in the original position of the stents.The migration of some stents was found .There were no obvious dysfunction in the adjacent organs.There were no serious abnormalities noted on blood tests.In the groups of radioactive pancreatic duct stents, the normal morphological structure of the pancreatic duct wall disappeared;In the groups of radioactive bile duct stents,perforation of the common bile duct was not observed and necrosis of mucosal layer existed.In 50Gy Group mild hyperplasia of mucosal glands was seen. In 100Gy Group almost no hyperplasia of the mucosal glands could be found. In 150Gy Group mucosal glands obviously decreased .Conclusions:The design of radioactive plastic stents is feasible;The radioactive stents are safe and feasible;It is feasible to design a special radioactive stent through TPS.
引文
1. Cotton PB, Williams CB. Endoscopic retrograde cholangio-pancreatography.In: Cotton PB, Williams CB (eds): Practical gastrointestinal endoscopy, 4th ed. Oxford: Blackwell Science, 1996;105–186.
2. Hafter E. Chronische Pankreatopathien–R?ntgenuntersuchung. In Hafter E (eds): Praktische Gastroenterologie. Stuttgart: Georg Thieme Verlag,1988;394–397.
3. Paul F, Simon W,et al. Die endoskopisch retrograde Cholangio-Pankreatikographie in der Diagnostik und Therapie von Pankreaserkrankungen.MedWelt 1993;44:54–59.
4.Summerfield JA.Biliary obstruction is best managed by endoscopists. Gut. 1988 Jun;29(6):741-5.
5.Vennes JA.Management of calculi in the common duct.Semin Liver Dis. 1983 May;3(2):162-71.
6.Cotton PB.Endoscopic management of bile duct stones; (apples and oranges).Gut. 1984 Jun;25(6):587-97.
7.Huibregtse K, Katon RM, Coene PP, Tytgat GN.Endoscopic palliative treatment in pancreatic cancer.Gastrointest Endosc. 1986 Oct;32(5):334-8.
8.Geenen JE, Hogan WJ, Dodds WJ, Toouli J, Venu RP.The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction.N Engl J Med. 1989 Jan 12;320(2):82-7.
9.Noar MD.An established porcine model for animate training in diagnostic and therapeutic ERCP.Endoscopy. 1995 Jan;27(1):77-80.
10.Gholson CF, Provenza JM, Silver RC, Bacon BR.Endoscopic retrograde cholangiography in the swine: a new model for endoscopic training and hepatobiliary research.Gastrointest Endosc. 1990 Nov-Dec;36(6):600-3.
11.Williams CB, Baillie J, Gillies DF, Borislow D, Cotton PB. Teaching gastrointestinal endoscopy by computer simulation: a prototype for colonoscopy and ERCP.Gastrointest Endosc. 1990 Jan-Feb;36(1):49-54.
12.Noar MD. Robotics interactive endoscopy simulation of ERCP/sphincterotomy and EGD.Endoscopy. 1992 Jul;24 Suppl 2:539-41.
13. Beer-Gabel M, Delmotte S, Muntlak L. Computer assisted training in endoscopy (C.A.T.E.): from a simulator to a learning station.Endoscopy. 1992 Jul;24 Suppl 2:534-8.
14. Sedlack R, Petersen B, Binmoeller K, Kolars J. A direct comparison of ERCP teaching models.Gastrointest Endosc. 2003 Jun;57(7):886-90.
15.Falkenstein DB, Abrams RM, Kessler RE, Jones B, Johnson G, Zimmon DS. Endoscopic retrograde cholangiopancreatography in the dog: a model for training and research.Gastrointest Endosc. 1974 Aug;21(1):25-6.
16.Siegel JH, Korsten MA.ERCP in a nonhuman primate.Gastrointest Endosc. 1989 Nov-Dec;35(6):557-9.
17.Dondelinger RF, Ghysels MP, Brisbois D, Donkers E, Snaps FR, Saunders J,Deviere J.Relevant radiological anatomy of the pig as a training model in interventional radiology.Eur Radiol. 1998;8(7):1254-73.
18.Griffith SL, Burney BT, Fry FJ, Franklin TD Jr.A large animal model (swine) to study the diagnosis and treatment of cholelithiasis.Invest Radiol. 1989 Feb;24(2):110-4.
19.Parasher VK, Toomey P, Clifton V, et al.Simulated sphincterotomy in a pig model.Gastrointest Endosc.1995 Mar;41(3):240-2.
20. Rumalla A, Petersen BT, Baron TH, et al.Development of a swine model for benign stenosis of the bile duct by endoscopic application of intraluminal thermal injury.Gastrointest Endosc. 2003 Jan;57(1):73-7.
21.Chen YK, Jakribettuu V, Springer EW, et al.Safety and efficacy of argon plasma coagulation trimming of malpositioned and migrated biliary metal stents: a controlled study in the porcine model.Am J Gastroenterol. 2006 Sep;101(9):2025-30.
1.Costamagna G, Gabbrielli A, et al. Treatment of "obstructive" pain by endoscopic drainage in patients with pancreatic head carcinoma.Gastrointest Endosc. 1993,39(6):774-7.
2.Tham TC,Lichtenstein DR,Vandervoort J,et al.Pancreatic duct stents for “obstructive type” pain in pancreatic malignancy.Am J Gastroenterol ,2000,95:956-960.
3.A dam A , Chetty N , Roddie M ,et al. Self-expandable stainless steel endprostheses for treatment of malignant bile obstruction .Am J Roentgenol, 1991, 156 (2) : 321
4. Mohinddin M, Rosato F, Barbot D, et al. Long term results of combined modality treatment with 125I implantation for carcinoma of the pancreas. Int. J Radiat Oncol Biol Phys, 1992,23:305-311
5. Radge H, Blasko JC, Grimm PD,et al. Brachytherapy for clinically localized prostate cancer: results at 7-and 8-year follow-up. Semmin Surg Pncol, 1997,13:438-43
6. MartinezM R, Nag S, Nieroda CA,et al. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer, 1999, 85: 1218-25
7. Videtic GM, Gaspar LE, Zamorano L,et al. Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. Int J Radiat Oncol Biol Phys, 1999,45:687-692
8. Aird EG, Folkard M, Mayes CR, Bownes PJ, Lawson JM, Joiner MC. A purpose-built iodine-125 irradiation plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol. 2001 Jan;74(877):56-61.
9. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS.Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995 Feb;22(2):209-34. No abstract available. Erratum in: Med Phys 1996 Sep;23(9):1579.
10. Wuu CS, Ennis RD, Schiff PB, Lee EK, Zaider M. Dosimetric and volumetric criteria for selecting a source activity and a source type ((125)I or (103)Pd) in the presence of irregular seed placement in permanent prostate implants. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):815-20.
11. Maeng M, Thuesen L, Andersen HR. [Treatment and prevention of restenosis after percutaneous coronary intervention. Balloons, stents, radioactive rays and drug-releasing stents] Ugeskr Laeger. 2005 Aug 15;167(33):3030-2.
12. Won JH, Lee JD, Wang HJ, Kim GE, Kim BW, Yim H, Han SK, Park CH, Joh CW, Kim KH, Park KB, Shin KM.Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):1005-13.
13. Won JH, Lee JD, Wang HJ, Han JH, Kim JH, Kim KH, Park KB, Itkin M. Effects of a holmium-166 incorporated covered stent placement in normal canine common bile ducts. J Vasc Interv Radiol. 2005 May;16(5):705-11.
14. Takacsi-Nagy Z, Varga J, Poller I, Fodor J, Polgar C, Petranyi A, Major T, Nemeth G. Successful treatment of a T1 cancer of the pancreatic head with high dose rate brachytherapy and external radiotherapy. Hepatogastroenterology. 2002 May-Jun;49(45):844-6.
15. Nori D, Merimsky O, Osian AD, Heffernan M, Cortes E, Turner JW. Palladium-103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase I-II study. J Surg Oncol. 1996 Apr;61(4):300-5.
16. Gholson CF, Provenza JM, Silver RC, Bacon BR. Endoscopic retrograde cholangiography in the swine: a new model for endoscopic training and hepatobiliary research. Gastrointest Endosc. 1990 Nov-Dec;36(6):600-3.
1. Freelove R, Walling AD. Pancreatic cancer: diagnosis and management.Am Fam Physician. 2006 Feb 1;73(3):485-92.
2. Tanaka M. Important clues to the diagnosis of pancreatic cancer. Rocz Akad Med Bialymst. 2005;50:69-72.
3. Vilaichone RK, Schulz HJ, Mahachai V. Endoscopic management of pancreatic cancer. J Med Assoc Thai. 2005 Sep;88 Suppl 4:S352-6.
4. Willett CG, Safran H, Abrams RA, Regine WF, Rich TA. Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys. 2003;56(4 Suppl):31-7.
5. Dobelbower RR, Montemaggi P. Brachytherapy for pancreatic cancer: a review. Hepatogastroenterology. 1996 Mar-Apr;43(8):333-7.
6. Takacsi-Nagy Z, Varga J, Poller I, Fodor J, Polgar C, Petranyi A, Major T, Nemeth G. Successful treatment of a T1 cancer of the pancreatic head with high dose rate brachytherapy and external radiotherapy. Hepatogastroenterology. 2002 May-Jun;49(45):844-6.
7. Aird EG, Folkard M, Mayes CR, Bownes PJ, Lawson JM, Joiner MC. A purpose-built iodine-125 irradiation plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol. 2001 Jan;74(877):56-61.
8. Dondelinger RF, Ghysels MP, Brisbois D, Donkers E, Snaps FR, Saunders J, Deviere J. Relevant radiological anatomy of the pig as a training model in interventional radiology. Eur Radiol. 1998;8(7):1254-73.
9. Nath R, Anderson LL,. Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995 Feb;22(2) :209-34. No abstract available. Erratum in: Med Phys 1996 Sep;23(9):1579.
10. Wuu CS, Ennis RD, Schiff PB, Lee EK, Zaider M. Dosimetric and volumetric criteria for selecting a source activity and a source type ((125) I or (103)Pd) in the presence of irregular seed placement in permanent prostate implants. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):815-20.
11. Tashchereau R, Roy R, Pouliot J. Relative biological effectiveness enhancement of a 125I brachytherapy seed with characteristic X rays from its constitutive materials. Med Phys 2002:29:1397-420.
12. Mutignani M, Shah SK, Morganti AG, Perri V, Macchia G, Costamagna G. Treatment of unresectable pancreatic carcinoma by intraluminal brachytherapy in the duct of Wirsung. Endoscopy. 2002 Jul;34(7):555-9.
13. Montemaggi P, Morganti AG, Dobelbower RR Jr, Brizi G, Smaniotto D, Costamagna G, Cellini N, Marano P. Role of intraluminal brachytherapy in extrahepatic bile duct and pancreatic cancers: is it just for palliation? Radiology. 1996 Jun;199(3):861-6.
14. Dvorak J, Petera J, Papik Z, Melichar B, Vanasek T, Hulek P, Jandik P, Mergancova J, Zoul Z, Vacek Z. Transduodenal intraluminal high dose rate brachytherapy in the treatment of carcinomas of the subhepatic region. Hepatogastroenterology. 2002 Jul-Aug;49(46):1045-7.
15. Zopf T, RiemannJF. [Therapy of pancreatic and bile duct tumors: value of radiotherapy and photodynamic therapy] Schweiz Rundsch Med Prax. 2000 Aug 17;89(33):1293-8.
16. Bodner WR, Hilaris BS, Mastoras DA. Radiation therapy in pancreatic cancer: current practice and future trends. J Clin Gastroenterol 2000; 30:230-3.
17. Sakurai H, Mitsuhashi N, Harashima K, et al. CT-fluoroscopy guided interstitial brachytherapy with image-based treatment planning for unresectable locally recurrent rectal carcinoma. Brachytherapy 2004;3: 222-30.
18. Hannoun-Levi JM, Houvenaeghel G, Ellis S, et al. Partial breast irradiation as second conservative treatment for local breast cancer recurrence. Int J Radiat Oncol Biol Phys 2004;60:1385-92.
19. Merrick GS, Butler WM, Wallner KE, et al. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA ! 20 ng/mL. Am J Clin Oncol 2004;27:611-5.
20. Viola A, Major T, Julow J. The importance of postoperative CT image fusion verification of stereotactic interstitial irradiation for brain tumors. Int J Radiat Oncol Biol Phys 2004;60:322-8.
21. Chan HH, Nishioka NS, Mino M, et al. EUS-guided photodynamic therapy of the pancreas: a pilot study. Gastrointest Endosc 2004;59:95-9.
22. Maeng M, Thuesen L, Andersen HR. [Treatment and prevention of restenosis after percutaneous coronary intervention. Balloons, stents, radioactive rays and drug-releasing stents] Ugeskr Laeger.2005 Aug 15;167(33):3030-2.
23. Won JH, Lee JD, Wang HJ, Kim GE, Kim BW, Yim H, Han SK, Park CH, Joh CW, Kim KH, Park KB, Shin KM.Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):1005-13.
24. Won JH, Lee JD, Wang HJ, Han JH, Kim JH, Kim KH, Park KB, Itkin M. Effects of a holmium-166 incorporated covered stent placement in normal canine common bile ducts. J Vasc Interv Radiol. 2005 May;16(5):705-11.
25. Nori D, Merimsky 0, Osian AD, Heffernan M, Cortes E, Turner JW. Palladium-103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase I—II study. J Surg Oncol. 1996 Apr;61(4):300-5.
26. Smits ME, Groen AK, Mok KS, van Marie J, Tytgat GN, Huibregtse K. Analysis of occluded pancreatic stents and juices in patients with chronic pancreatitis. Gastrointest Endosc. 1997 Jan;45(1):52-8.
27. Kozarek R, Hovde 0, AttiaF, France R. Do pancreatic duct stents cause or prevent pancreatic sepsis? Gastrointest Endosc. 2003 0ct;58(4):505-9.
28. Gholson CF, Provenza JM, Silver RC, Bacon BR. Endoscopic retrograde cholangiography in the swine: a new model for endoscopic training and hepatobiliary research. Gastrointest Endosc. 1990 Nov-Dec;36(6):600-3.
1. Lee CK, Barrios BR, Bjarnason H. Biliary tree malignancies:The University of Minnesota experience. J Surg Oncol 1997;65:298-305.
2. Erickson BA, Nag S. Biliary tree malignancies. J Surg Oncol 1998:67:203-210.
3. Ishii H, Furuse J, Nagase M, Kawashima M, Ikeda H, Yoshino M. Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting.Hepatogastroenterology. 2004 Jul-Aug;51(58):954-7.
4. Takamura A, Saito H, Kamada T, Hiramatsu K, Takeuchi S, Hasegawa M, Miyamoto N. lntraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1357-65.
5. Shin HS, Seong J, Kim WC, Lee HS, Moon SR, Lee IJ, Lee KK, Park KR, Suh CO, Kim GE. Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):105-12.
6. Aird EG, Folkard M, Mayes CR, Bownes PJ, Lawson JM, Joiner MC. A purpose-built iodine-125 irradiation plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol. 2001 Jan;74(877):56-61.
7. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995 Feb;22(2) :209-34. No abstract available. Erratum in: Med Phys . 1996 Sep;23(9):1579.
8. Wuu CS, Ennis RD, Schiff PB, Lee EK, Zaider M. Dosimetric and volumetric criteria for selecting a source activity and a source type ((125) I or (103)Pd) in the presence of irregular seed placement in permanent prostate implants. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3) :815-20.
9. Tashchereau R, Roy R, Pouliot J. Relative biological effectiveness enhancement of a 125I brachytherapy seed with characteristic X rays from its constitutive materials. Med Phys 2002;29:1397-420.
10. Mutignani M, Shah SK, Morganti AG, Perri V, Macchia G, Costamagna G. Treatment of unresectable pancreatic carcinoma by intraluminal brachytherapy in the duct of Wirsung. Endoscopy. 2002 Jul;34(7):555-9.
11. Dvorak J, Petera J, Papik Z, Melichar B, Vanasek T, Hulek P, Jandik P, Mergancova J, Zoul Z, Vacek Z. Transduodenal intraluminal high dose rate brachytherapy in the treatment of carcinomas of the subhepatic region. Hepatogastroenterology. 2002 Jul-Aug;49(46):1045-7.
12. Zopf T, RiemannJF. [Therapy of pancreatic and bile duct tumors: value of radiotherapy and photodynamic therapy] Schweiz Rundsch Med Prax. 2000 Aug 17;89 (33):1293-8.
13. Chen Y, Wang XL, Yan ZP, Cheng JM, Wang JH, Gong GQ, Qian S, Luo JJ,Liu QX. HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice. World J Gastroenterol. 2004 Dec 1;10(23):3506-10.
14. Leung JT, Kuan R. Intraluminal brachytherapy in the treatment of bile duct carcinomas. Australas Radiol. 1997 May;41(2):151-4.
15.Kocak Z, Ozkan H, Adli M, Garipagaoglu M, Kurtman C, Cakmak A. Intraluminal brachytherapy with metallic stenting in the palliative treatment of malignant obstruction of the bile duct. Radiat Med. 2005 May;23(3):200-7.
16. Morganti AG, Trodella L, Valentini V, Montemaggi P, Costamagna G, Smaniotto D, Luzi S, Ziccarelli P, Macchia G, Perri V, Mutignani M, Cellini N. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):913-9.
17. Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer.Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4) :945-51.
18. Maeng M, Thuesen L, Andersen HR. [Treatment and prevention of restenosis after percutaneous coronary intervention. Balloons, stents, radioactive rays and drug-releasing stents] Ugeskr Laeger.2005 Aug 15:167(33):3030-2.
19. Won JH, Lee JD, Wang HJ, Kim GE, Kim BW, Yim H, Han SK, Park CH, Joh CW, Kim KH, Park KB, Shin KM. Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):1005-13.
20. Won JH, Lee JD, Wang HJ, Han JH, Kim JH, Kim KH, Park KB, Itkin M. Effects of a holmium-166 incorporated covered stent placement in normal canine common bile ducts. J Vase Interv Radiol. 2005 May; 16 (5): 705-11.
21. Eschelman DJ, Shapiro MJ, Bonn J, Sullivan KL, Alden ME, Hovsepian DM, Gardiner GA Jr.Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined-modality radiation therapy. Radiology. 1996 Sep;200(3):717-24.
22. Carter AJ, Laird JR, Bailey LR, et al. Effects of endovascular radiation from a β-particle-emitting stent in a porcine coronary restenosis model:a dose-response study. Circulation, 1996; 94: 2364
23. Gholson CF, Provenza JM, Silver RC, Bacon BR. Endoscopic retrograde cholangiography in the swine: a new model for endoscopic training and hepatobiliary research. Gastrointest Endosc. 1990 Nov-Dec;36(6):600-3.
1. Parkin DM, Bray FI, Evesa SS. Cancer burden in the year 2000. The global picture [ J ]. Eur J Cancer, 2001, 37: 54-66.
2. Cooperman AM. Pancreatic cancer: the bigger picture [ J ].Surg Clin North Am, 2001, 81: 557-574.
3. Nag S, Sasha D, Janjan N, et al. The American Brachytherapy Society' s recommendations for brachytherapy of soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2001;49:1033-1043.
4. Waring JS. LDR/HDR brachytherapy. In: Bruner DW, Haas ML, Gosselin-Acomb TK, eds: Manual for Radiation Oncology Nursing Practice and Education. Ed 3. Pittsburgh, PA:0ncology Nursing Society: 2005:160-168.
5. Mutignani M, Shah SK, Morganti AG,et al. Treatment of unresectable pancreatic carcinoma by intraluminal brachytherapy in the duct of Wirsung. Endoscopy [J ]. 2002 ,34(7):555-9.
6. Peretz T, Nori D, Hilaris B, et al. Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys 1989;17:931-5.
7. Hilaris B, Roussis K. Cancer of the pancreas. In: Hilaris B, ed.Handbook of interstitial brachytherapy. Acton, MS: Publishing Sciences Group, Inc,1975:251-62.
8.Siegel JH, Lichtenstein JL,Pullano WE,et al. Treatment of malignant biliary obstruction by endoscopic implantation of iridium 192 using a new double lumen endoprosthesis. Gastrointest Endosc 1988; 34:301-306
9.Levitt MD, Laurence BH, Cameron F, et al. Transpapillary iridium-192 . wire in the treatment of malignant bile duct obstruction. Gut 1988;29:149-152
10. Montemaggi P, Costamagna G, Dobelbower RR, et al. Intraluminal brachytherapy in the treatment of pancreas and bile duct carcinoma.Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):437-43.
11. Montemaggi P, Morganti AG, Dobelbower RR, et al. Role of intraluminal brachytherapy in extrahepatic bile duct and pancreatic cancers: is it just for palliation? Radiology 1996; 191: 861-866
12. Sun S, Xu H, Xin J, et al. Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial. Endoscopy. 2006 ,38(4):399-403.
13. Pasteau 0, Degrais P :The radium treatment of cancer of the prostate. Arch Roentgen Ray ,1914 ;28 :396 - 410.
14.Flocks RH , Kerr HD,Elkins HB,et al. Treatment of carcinoma of the prostate by interstitial radiation with radioactive gold(Au - 198) :a preliminary report . J Urol ,1952 ,68 :510 - 522.
15. Whittington R, Solin L, Mohiuddin M, et al: Multimodality treatment of localized unresectable pancreatic adenocarcinoma. Cancer 1984:54:1991 -1998.
16. Shipley WU, Nardi GL, Cohen AM, et al. Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: a comparative study to surgical resection. Cancer 1980:45:709-714.
17.Handley SW. Pancreatic caner and the treatment by implanted radium. Ann Surg,1934,100:215-222.
18. Peck GT, McNeil G. Radiation treatment for pancreatic cancer. Am J Roentgenol, 1938,40:708-715.
19.Barone RM. Treatment of carcinoma of the pancreas with radon seed implantation and intra-arterial infusion of 5-FUDR. Surg Clin North Am. 1975 Feb;55(l):117-26.
20. Syed AM, Puthawala AA, Neblett DL. Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma. Cancer. 1983 Sep 1:52(5): 808-13.
21. Sun S, Qingjie L, Qiyong G, et al. EUS-guided interstitial brachytherapy of the pancreas: a feasibility study.Gastrointest Endosc. 2005 Nov;62 (5):775-9.
22.Sun S, Xu H, Xin J, et al. Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial. Endoscopy. 2006 Apr;38(4):399-403.
2. Hafter E. Chronische Pankreatopathien–R?ntgenuntersuchung. In Hafter E (eds): Praktische Gastroenterologie. Stuttgart: Georg Thieme Verlag,1988;394–397.
3. Paul F, Simon W,et al. Die endoskopisch retrograde Cholangio-Pankreatikographie in der Diagnostik und Therapie von Pankreaserkrankungen.MedWelt 1993;44:54–59.
4.Summerfield JA.Biliary obstruction is best managed by endoscopists. Gut. 1988 Jun;29(6):741-5.
5.Vennes JA.Management of calculi in the common duct.Semin Liver Dis. 1983 May;3(2):162-71.
6.Cotton PB.Endoscopic management of bile duct stones; (apples and oranges).Gut. 1984 Jun;25(6):587-97.
7.Huibregtse K, Katon RM, Coene PP, Tytgat GN.Endoscopic palliative treatment in pancreatic cancer.Gastrointest Endosc. 1986 Oct;32(5):334-8.
8.Geenen JE, Hogan WJ, Dodds WJ, Toouli J, Venu RP.The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction.N Engl J Med. 1989 Jan 12;320(2):82-7.
9.Noar MD.An established porcine model for animate training in diagnostic and therapeutic ERCP.Endoscopy. 1995 Jan;27(1):77-80.
10.Gholson CF, Provenza JM, Silver RC, Bacon BR.Endoscopic retrograde cholangiography in the swine: a new model for endoscopic training and hepatobiliary research.Gastrointest Endosc. 1990 Nov-Dec;36(6):600-3.
11.Williams CB, Baillie J, Gillies DF, Borislow D, Cotton PB. Teaching gastrointestinal endoscopy by computer simulation: a prototype for colonoscopy and ERCP.Gastrointest Endosc. 1990 Jan-Feb;36(1):49-54.
12.Noar MD. Robotics interactive endoscopy simulation of ERCP/sphincterotomy and EGD.Endoscopy. 1992 Jul;24 Suppl 2:539-41.
13. Beer-Gabel M, Delmotte S, Muntlak L. Computer assisted training in endoscopy (C.A.T.E.): from a simulator to a learning station.Endoscopy. 1992 Jul;24 Suppl 2:534-8.
14. Sedlack R, Petersen B, Binmoeller K, Kolars J. A direct comparison of ERCP teaching models.Gastrointest Endosc. 2003 Jun;57(7):886-90.
15.Falkenstein DB, Abrams RM, Kessler RE, Jones B, Johnson G, Zimmon DS. Endoscopic retrograde cholangiopancreatography in the dog: a model for training and research.Gastrointest Endosc. 1974 Aug;21(1):25-6.
16.Siegel JH, Korsten MA.ERCP in a nonhuman primate.Gastrointest Endosc. 1989 Nov-Dec;35(6):557-9.
17.Dondelinger RF, Ghysels MP, Brisbois D, Donkers E, Snaps FR, Saunders J,Deviere J.Relevant radiological anatomy of the pig as a training model in interventional radiology.Eur Radiol. 1998;8(7):1254-73.
18.Griffith SL, Burney BT, Fry FJ, Franklin TD Jr.A large animal model (swine) to study the diagnosis and treatment of cholelithiasis.Invest Radiol. 1989 Feb;24(2):110-4.
19.Parasher VK, Toomey P, Clifton V, et al.Simulated sphincterotomy in a pig model.Gastrointest Endosc.1995 Mar;41(3):240-2.
20. Rumalla A, Petersen BT, Baron TH, et al.Development of a swine model for benign stenosis of the bile duct by endoscopic application of intraluminal thermal injury.Gastrointest Endosc. 2003 Jan;57(1):73-7.
21.Chen YK, Jakribettuu V, Springer EW, et al.Safety and efficacy of argon plasma coagulation trimming of malpositioned and migrated biliary metal stents: a controlled study in the porcine model.Am J Gastroenterol. 2006 Sep;101(9):2025-30.
1.Costamagna G, Gabbrielli A, et al. Treatment of "obstructive" pain by endoscopic drainage in patients with pancreatic head carcinoma.Gastrointest Endosc. 1993,39(6):774-7.
2.Tham TC,Lichtenstein DR,Vandervoort J,et al.Pancreatic duct stents for “obstructive type” pain in pancreatic malignancy.Am J Gastroenterol ,2000,95:956-960.
3.A dam A , Chetty N , Roddie M ,et al. Self-expandable stainless steel endprostheses for treatment of malignant bile obstruction .Am J Roentgenol, 1991, 156 (2) : 321
4. Mohinddin M, Rosato F, Barbot D, et al. Long term results of combined modality treatment with 125I implantation for carcinoma of the pancreas. Int. J Radiat Oncol Biol Phys, 1992,23:305-311
5. Radge H, Blasko JC, Grimm PD,et al. Brachytherapy for clinically localized prostate cancer: results at 7-and 8-year follow-up. Semmin Surg Pncol, 1997,13:438-43
6. MartinezM R, Nag S, Nieroda CA,et al. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer, 1999, 85: 1218-25
7. Videtic GM, Gaspar LE, Zamorano L,et al. Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. Int J Radiat Oncol Biol Phys, 1999,45:687-692
8. Aird EG, Folkard M, Mayes CR, Bownes PJ, Lawson JM, Joiner MC. A purpose-built iodine-125 irradiation plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol. 2001 Jan;74(877):56-61.
9. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS.Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995 Feb;22(2):209-34. No abstract available. Erratum in: Med Phys 1996 Sep;23(9):1579.
10. Wuu CS, Ennis RD, Schiff PB, Lee EK, Zaider M. Dosimetric and volumetric criteria for selecting a source activity and a source type ((125)I or (103)Pd) in the presence of irregular seed placement in permanent prostate implants. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):815-20.
11. Maeng M, Thuesen L, Andersen HR. [Treatment and prevention of restenosis after percutaneous coronary intervention. Balloons, stents, radioactive rays and drug-releasing stents] Ugeskr Laeger. 2005 Aug 15;167(33):3030-2.
12. Won JH, Lee JD, Wang HJ, Kim GE, Kim BW, Yim H, Han SK, Park CH, Joh CW, Kim KH, Park KB, Shin KM.Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):1005-13.
13. Won JH, Lee JD, Wang HJ, Han JH, Kim JH, Kim KH, Park KB, Itkin M. Effects of a holmium-166 incorporated covered stent placement in normal canine common bile ducts. J Vasc Interv Radiol. 2005 May;16(5):705-11.
14. Takacsi-Nagy Z, Varga J, Poller I, Fodor J, Polgar C, Petranyi A, Major T, Nemeth G. Successful treatment of a T1 cancer of the pancreatic head with high dose rate brachytherapy and external radiotherapy. Hepatogastroenterology. 2002 May-Jun;49(45):844-6.
15. Nori D, Merimsky O, Osian AD, Heffernan M, Cortes E, Turner JW. Palladium-103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase I-II study. J Surg Oncol. 1996 Apr;61(4):300-5.
16. Gholson CF, Provenza JM, Silver RC, Bacon BR. Endoscopic retrograde cholangiography in the swine: a new model for endoscopic training and hepatobiliary research. Gastrointest Endosc. 1990 Nov-Dec;36(6):600-3.
1. Freelove R, Walling AD. Pancreatic cancer: diagnosis and management.Am Fam Physician. 2006 Feb 1;73(3):485-92.
2. Tanaka M. Important clues to the diagnosis of pancreatic cancer. Rocz Akad Med Bialymst. 2005;50:69-72.
3. Vilaichone RK, Schulz HJ, Mahachai V. Endoscopic management of pancreatic cancer. J Med Assoc Thai. 2005 Sep;88 Suppl 4:S352-6.
4. Willett CG, Safran H, Abrams RA, Regine WF, Rich TA. Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys. 2003;56(4 Suppl):31-7.
5. Dobelbower RR, Montemaggi P. Brachytherapy for pancreatic cancer: a review. Hepatogastroenterology. 1996 Mar-Apr;43(8):333-7.
6. Takacsi-Nagy Z, Varga J, Poller I, Fodor J, Polgar C, Petranyi A, Major T, Nemeth G. Successful treatment of a T1 cancer of the pancreatic head with high dose rate brachytherapy and external radiotherapy. Hepatogastroenterology. 2002 May-Jun;49(45):844-6.
7. Aird EG, Folkard M, Mayes CR, Bownes PJ, Lawson JM, Joiner MC. A purpose-built iodine-125 irradiation plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol. 2001 Jan;74(877):56-61.
8. Dondelinger RF, Ghysels MP, Brisbois D, Donkers E, Snaps FR, Saunders J, Deviere J. Relevant radiological anatomy of the pig as a training model in interventional radiology. Eur Radiol. 1998;8(7):1254-73.
9. Nath R, Anderson LL,. Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995 Feb;22(2) :209-34. No abstract available. Erratum in: Med Phys 1996 Sep;23(9):1579.
10. Wuu CS, Ennis RD, Schiff PB, Lee EK, Zaider M. Dosimetric and volumetric criteria for selecting a source activity and a source type ((125) I or (103)Pd) in the presence of irregular seed placement in permanent prostate implants. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):815-20.
11. Tashchereau R, Roy R, Pouliot J. Relative biological effectiveness enhancement of a 125I brachytherapy seed with characteristic X rays from its constitutive materials. Med Phys 2002:29:1397-420.
12. Mutignani M, Shah SK, Morganti AG, Perri V, Macchia G, Costamagna G. Treatment of unresectable pancreatic carcinoma by intraluminal brachytherapy in the duct of Wirsung. Endoscopy. 2002 Jul;34(7):555-9.
13. Montemaggi P, Morganti AG, Dobelbower RR Jr, Brizi G, Smaniotto D, Costamagna G, Cellini N, Marano P. Role of intraluminal brachytherapy in extrahepatic bile duct and pancreatic cancers: is it just for palliation? Radiology. 1996 Jun;199(3):861-6.
14. Dvorak J, Petera J, Papik Z, Melichar B, Vanasek T, Hulek P, Jandik P, Mergancova J, Zoul Z, Vacek Z. Transduodenal intraluminal high dose rate brachytherapy in the treatment of carcinomas of the subhepatic region. Hepatogastroenterology. 2002 Jul-Aug;49(46):1045-7.
15. Zopf T, RiemannJF. [Therapy of pancreatic and bile duct tumors: value of radiotherapy and photodynamic therapy] Schweiz Rundsch Med Prax. 2000 Aug 17;89(33):1293-8.
16. Bodner WR, Hilaris BS, Mastoras DA. Radiation therapy in pancreatic cancer: current practice and future trends. J Clin Gastroenterol 2000; 30:230-3.
17. Sakurai H, Mitsuhashi N, Harashima K, et al. CT-fluoroscopy guided interstitial brachytherapy with image-based treatment planning for unresectable locally recurrent rectal carcinoma. Brachytherapy 2004;3: 222-30.
18. Hannoun-Levi JM, Houvenaeghel G, Ellis S, et al. Partial breast irradiation as second conservative treatment for local breast cancer recurrence. Int J Radiat Oncol Biol Phys 2004;60:1385-92.
19. Merrick GS, Butler WM, Wallner KE, et al. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA ! 20 ng/mL. Am J Clin Oncol 2004;27:611-5.
20. Viola A, Major T, Julow J. The importance of postoperative CT image fusion verification of stereotactic interstitial irradiation for brain tumors. Int J Radiat Oncol Biol Phys 2004;60:322-8.
21. Chan HH, Nishioka NS, Mino M, et al. EUS-guided photodynamic therapy of the pancreas: a pilot study. Gastrointest Endosc 2004;59:95-9.
22. Maeng M, Thuesen L, Andersen HR. [Treatment and prevention of restenosis after percutaneous coronary intervention. Balloons, stents, radioactive rays and drug-releasing stents] Ugeskr Laeger.2005 Aug 15;167(33):3030-2.
23. Won JH, Lee JD, Wang HJ, Kim GE, Kim BW, Yim H, Han SK, Park CH, Joh CW, Kim KH, Park KB, Shin KM.Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):1005-13.
24. Won JH, Lee JD, Wang HJ, Han JH, Kim JH, Kim KH, Park KB, Itkin M. Effects of a holmium-166 incorporated covered stent placement in normal canine common bile ducts. J Vasc Interv Radiol. 2005 May;16(5):705-11.
25. Nori D, Merimsky 0, Osian AD, Heffernan M, Cortes E, Turner JW. Palladium-103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase I—II study. J Surg Oncol. 1996 Apr;61(4):300-5.
26. Smits ME, Groen AK, Mok KS, van Marie J, Tytgat GN, Huibregtse K. Analysis of occluded pancreatic stents and juices in patients with chronic pancreatitis. Gastrointest Endosc. 1997 Jan;45(1):52-8.
27. Kozarek R, Hovde 0, AttiaF, France R. Do pancreatic duct stents cause or prevent pancreatic sepsis? Gastrointest Endosc. 2003 0ct;58(4):505-9.
28. Gholson CF, Provenza JM, Silver RC, Bacon BR. Endoscopic retrograde cholangiography in the swine: a new model for endoscopic training and hepatobiliary research. Gastrointest Endosc. 1990 Nov-Dec;36(6):600-3.
1. Lee CK, Barrios BR, Bjarnason H. Biliary tree malignancies:The University of Minnesota experience. J Surg Oncol 1997;65:298-305.
2. Erickson BA, Nag S. Biliary tree malignancies. J Surg Oncol 1998:67:203-210.
3. Ishii H, Furuse J, Nagase M, Kawashima M, Ikeda H, Yoshino M. Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting.Hepatogastroenterology. 2004 Jul-Aug;51(58):954-7.
4. Takamura A, Saito H, Kamada T, Hiramatsu K, Takeuchi S, Hasegawa M, Miyamoto N. lntraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1357-65.
5. Shin HS, Seong J, Kim WC, Lee HS, Moon SR, Lee IJ, Lee KK, Park KR, Suh CO, Kim GE. Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):105-12.
6. Aird EG, Folkard M, Mayes CR, Bownes PJ, Lawson JM, Joiner MC. A purpose-built iodine-125 irradiation plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol. 2001 Jan;74(877):56-61.
7. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995 Feb;22(2) :209-34. No abstract available. Erratum in: Med Phys . 1996 Sep;23(9):1579.
8. Wuu CS, Ennis RD, Schiff PB, Lee EK, Zaider M. Dosimetric and volumetric criteria for selecting a source activity and a source type ((125) I or (103)Pd) in the presence of irregular seed placement in permanent prostate implants. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3) :815-20.
9. Tashchereau R, Roy R, Pouliot J. Relative biological effectiveness enhancement of a 125I brachytherapy seed with characteristic X rays from its constitutive materials. Med Phys 2002;29:1397-420.
10. Mutignani M, Shah SK, Morganti AG, Perri V, Macchia G, Costamagna G. Treatment of unresectable pancreatic carcinoma by intraluminal brachytherapy in the duct of Wirsung. Endoscopy. 2002 Jul;34(7):555-9.
11. Dvorak J, Petera J, Papik Z, Melichar B, Vanasek T, Hulek P, Jandik P, Mergancova J, Zoul Z, Vacek Z. Transduodenal intraluminal high dose rate brachytherapy in the treatment of carcinomas of the subhepatic region. Hepatogastroenterology. 2002 Jul-Aug;49(46):1045-7.
12. Zopf T, RiemannJF. [Therapy of pancreatic and bile duct tumors: value of radiotherapy and photodynamic therapy] Schweiz Rundsch Med Prax. 2000 Aug 17;89 (33):1293-8.
13. Chen Y, Wang XL, Yan ZP, Cheng JM, Wang JH, Gong GQ, Qian S, Luo JJ,Liu QX. HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice. World J Gastroenterol. 2004 Dec 1;10(23):3506-10.
14. Leung JT, Kuan R. Intraluminal brachytherapy in the treatment of bile duct carcinomas. Australas Radiol. 1997 May;41(2):151-4.
15.Kocak Z, Ozkan H, Adli M, Garipagaoglu M, Kurtman C, Cakmak A. Intraluminal brachytherapy with metallic stenting in the palliative treatment of malignant obstruction of the bile duct. Radiat Med. 2005 May;23(3):200-7.
16. Morganti AG, Trodella L, Valentini V, Montemaggi P, Costamagna G, Smaniotto D, Luzi S, Ziccarelli P, Macchia G, Perri V, Mutignani M, Cellini N. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):913-9.
17. Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer.Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4) :945-51.
18. Maeng M, Thuesen L, Andersen HR. [Treatment and prevention of restenosis after percutaneous coronary intervention. Balloons, stents, radioactive rays and drug-releasing stents] Ugeskr Laeger.2005 Aug 15:167(33):3030-2.
19. Won JH, Lee JD, Wang HJ, Kim GE, Kim BW, Yim H, Han SK, Park CH, Joh CW, Kim KH, Park KB, Shin KM. Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):1005-13.
20. Won JH, Lee JD, Wang HJ, Han JH, Kim JH, Kim KH, Park KB, Itkin M. Effects of a holmium-166 incorporated covered stent placement in normal canine common bile ducts. J Vase Interv Radiol. 2005 May; 16 (5): 705-11.
21. Eschelman DJ, Shapiro MJ, Bonn J, Sullivan KL, Alden ME, Hovsepian DM, Gardiner GA Jr.Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined-modality radiation therapy. Radiology. 1996 Sep;200(3):717-24.
22. Carter AJ, Laird JR, Bailey LR, et al. Effects of endovascular radiation from a β-particle-emitting stent in a porcine coronary restenosis model:a dose-response study. Circulation, 1996; 94: 2364
23. Gholson CF, Provenza JM, Silver RC, Bacon BR. Endoscopic retrograde cholangiography in the swine: a new model for endoscopic training and hepatobiliary research. Gastrointest Endosc. 1990 Nov-Dec;36(6):600-3.
1. Parkin DM, Bray FI, Evesa SS. Cancer burden in the year 2000. The global picture [ J ]. Eur J Cancer, 2001, 37: 54-66.
2. Cooperman AM. Pancreatic cancer: the bigger picture [ J ].Surg Clin North Am, 2001, 81: 557-574.
3. Nag S, Sasha D, Janjan N, et al. The American Brachytherapy Society' s recommendations for brachytherapy of soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2001;49:1033-1043.
4. Waring JS. LDR/HDR brachytherapy. In: Bruner DW, Haas ML, Gosselin-Acomb TK, eds: Manual for Radiation Oncology Nursing Practice and Education. Ed 3. Pittsburgh, PA:0ncology Nursing Society: 2005:160-168.
5. Mutignani M, Shah SK, Morganti AG,et al. Treatment of unresectable pancreatic carcinoma by intraluminal brachytherapy in the duct of Wirsung. Endoscopy [J ]. 2002 ,34(7):555-9.
6. Peretz T, Nori D, Hilaris B, et al. Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys 1989;17:931-5.
7. Hilaris B, Roussis K. Cancer of the pancreas. In: Hilaris B, ed.Handbook of interstitial brachytherapy. Acton, MS: Publishing Sciences Group, Inc,1975:251-62.
8.Siegel JH, Lichtenstein JL,Pullano WE,et al. Treatment of malignant biliary obstruction by endoscopic implantation of iridium 192 using a new double lumen endoprosthesis. Gastrointest Endosc 1988; 34:301-306
9.Levitt MD, Laurence BH, Cameron F, et al. Transpapillary iridium-192 . wire in the treatment of malignant bile duct obstruction. Gut 1988;29:149-152
10. Montemaggi P, Costamagna G, Dobelbower RR, et al. Intraluminal brachytherapy in the treatment of pancreas and bile duct carcinoma.Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):437-43.
11. Montemaggi P, Morganti AG, Dobelbower RR, et al. Role of intraluminal brachytherapy in extrahepatic bile duct and pancreatic cancers: is it just for palliation? Radiology 1996; 191: 861-866
12. Sun S, Xu H, Xin J, et al. Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial. Endoscopy. 2006 ,38(4):399-403.
13. Pasteau 0, Degrais P :The radium treatment of cancer of the prostate. Arch Roentgen Ray ,1914 ;28 :396 - 410.
14.Flocks RH , Kerr HD,Elkins HB,et al. Treatment of carcinoma of the prostate by interstitial radiation with radioactive gold(Au - 198) :a preliminary report . J Urol ,1952 ,68 :510 - 522.
15. Whittington R, Solin L, Mohiuddin M, et al: Multimodality treatment of localized unresectable pancreatic adenocarcinoma. Cancer 1984:54:1991 -1998.
16. Shipley WU, Nardi GL, Cohen AM, et al. Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: a comparative study to surgical resection. Cancer 1980:45:709-714.
17.Handley SW. Pancreatic caner and the treatment by implanted radium. Ann Surg,1934,100:215-222.
18. Peck GT, McNeil G. Radiation treatment for pancreatic cancer. Am J Roentgenol, 1938,40:708-715.
19.Barone RM. Treatment of carcinoma of the pancreas with radon seed implantation and intra-arterial infusion of 5-FUDR. Surg Clin North Am. 1975 Feb;55(l):117-26.
20. Syed AM, Puthawala AA, Neblett DL. Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma. Cancer. 1983 Sep 1:52(5): 808-13.
21. Sun S, Qingjie L, Qiyong G, et al. EUS-guided interstitial brachytherapy of the pancreas: a feasibility study.Gastrointest Endosc. 2005 Nov;62 (5):775-9.
22.Sun S, Xu H, Xin J, et al. Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial. Endoscopy. 2006 Apr;38(4):399-403.